

DAFTAR PUSTAKA

1. Kumar V, Abbas AK, Aster JC, editors. Robbins and Cotran pathologic basis of disease. Ninth edition. Philadelphia, PA: Elsevier/Saunders; 2015. p.1391.
2. Holger Moch, Peter A. Humphrey, Thomas M. Ulbright, Victor E. Reuter. WHO classification of tumours of the urinary system and male genital organs. 4th edition. Lyon: International Agency for Research on Cancer (IARC); 2016.
3. Magi-Galluzzi C, Zhou M. Genitourinary pathology. 2015. p. 200-14.
4. Al-Husseini MJ, Kunbaz A, Saad AM, Santos JV, Salahia S, Iqbal M, et al. Trends in the incidence and mortality of transitional cell carcinoma of the bladder for the last four decades in the USA: a SEER-based analysis. BMC Cancer. 2019 Dec; 19(1):46.
5. Huang Z, Zhang M, Chen G, Wang W, Zhang P, Yue Y, et al. Bladder cancer cells interact with vascular endothelial cells triggering EGFR signals to promote tumor progression. Int J Oncol. 2019 Feb 27.
6. Redondo-Gonzalez E, de Castro LN, Moreno-Sierra J, Maestro de las Casas ML, Vera-Gonzalez V, Ferrari DG, et al. Bladder carcinoma data with clinical risk factors and molecular markers: A Cluster Analysis. BioMed Research International. 2015. p. 1–14.
7. Kanker di Indonesia tahun 2014 data histopatologik. Jakarta: Badan Registrasi Kanker Perhimpunan Dokter Spesialis Patologi Indonesia; 2018.
8. Mirzaei H, Sabetrasedeh P, Sabetrasedeh P, Parvin M, Torbati P, Hajian P. Prevalence of the vascular endothelial growth factor receptor (VEGER) in transitional cell carcinoma (TCC) of bladder and its relationship with other prognostic factors. Int J Cancer Manag. 2018 Sep 17.
9. Zhao M, He X-L, Teng X-D. Understanding the molecular pathogenesis and prognostics of bladder cancer: an overview. Chin J Cancer Res. 2016;28(1):7.
10. Compérat EM, Burger M, Gontero P, Mostafid AH, Palou J, Rouprêt M, et al. Grading of urothelial carcinoma and the new “World health organisation classification of tumours of the urinary system and male genital organs 2016.” European Urology Focus. 2019 May; 5(3): p. 457–66.

11. Kaseb H, Aeddula NR. Bladder cancer. StatPearls: StatPearls Publishing; 2020.
12. Tanaka T, Miyazawa K, Tsukamoto T, Kuno T, Suzuki K. Pathobiology and chemoprevention of bladder cancer. *Journal of Oncology*. 2011. p. 1–23.
13. Kompier LC, Lurkin I, van der Aa MNM, van Rhijn BWG, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. Cheriyath V, editor. *PLoS ONE*. 2010 Nov 3; 5(11):e13821.
14. Afonso J, Lara L, Longatto-Filho A. Angiogenesis, lymphangiogenesis and lymphovascular invasion: Prognostic impact for bladder cancer patients. In: Canda AE, editor. *Bladder Cancer - From Basic Science to Robotic Surgery*. InTech; 2012.
15. Ukai R, Hashimoto K, Nakayama H, Iwamoto T. Lymphovascular invasion predicts poor prognosis in high-grade pT1 bladder cancer patients who underwent transurethral resection in one piece. *Jpn J Clin Oncol*. 2017 May 1; 47(5): p. 447–52.
16. Yuk HD, Jeong CW, Kwak C, Kim HH, Ku JH. Lymphovascular invasion have a similar prognostic value as lymph node involvement in patients undergoing radical cystectomy with urothelial carcinoma. *Scientific Reports*. 2018 Dec; 8(1).
17. Fukumoto K, Kikuchi E, Mikami S, Miyajima A, Oya M. Lymphovascular invasion status at transurethral resection of bladder tumors may predict subsequent poor response of T1 tumors to bacillus Calmette-Guérin. *BMC Urol*. 2016 Dec; 16(1):5.
18. Mazzuchelli R, Cheng L, Beltran A, Scarpelli M, Montironi R. Clinicopathological significance of lymphovascular invasion of urothelial carcinoma. *Anal Qu Cyt Histol*. 2012;34: p. 173-9.
19. Leissner J, Koeppen C, Wolf HK. Prognostic significance of vascular and perineuralinvasion in urothelial bladder cancer treated with radical cystectomy. *J Urol*. 2003;169: p. 955–60.
20. Bassi P, Ferrante GD, Piazza N, et al. Prognostic factors of outcome after radicalcystectomy for bladder cancer: a retrospective study of a homogeneous patientcohort. *J Urol*. 1999;161: p. 1494–7.

21. Kim HS, Kim M, Jeong CW, Kwak C, Kim HH, Ku JH. Presence of lymphovascular invasion in urothelial bladder cancer specimens after transurethral resections correlates with risk of upstaging and survival: A systematic review and meta-analysis. *Urologic Oncology: Seminars and Original Investigations*. 2014 Nov; 32(8): p. 1191–9.
22. Mazzucchelli R, Scarpelli M, Lopez-Beltran A, Cheng L, Di Primio R, Montironi R. A contemporary update and pathology reporting for urinary bladder cancer. *Int J Immunopathol Pharmacol*. 2012 Jul; 25(3): p. 565–71.
23. Piulats J, Mitjans F. Angiogenesis switch pathways. New Jersey : Humana Press. 2008. p.239-51.
24. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in Tumor Growth and Angiogenesis. *JCO*. 2005 Feb 10; 23(5): p. 1011–27.
25. Lukasz PF, Barbara G. Role of angiogenesis in urothelial bladder carcinoma. *CEJU*. 2016; 830.php
26. Behl V, Harsh M, Chauhan N, Biswas M. Expression of VEGF in patients of urinary bladder carcinoma. *jebmh*. 2017 Jul 11; 4(56): p. 3393–6.
27. Poyet C, Thomas L, Benoit TM, Aquino Delmo D, Luberto L, Banzola I, et al. Implication of vascular endothelial growth factor A and C in revealing diagnostic lymphangiogenic markers in node-positive bladder cancer. *Oncotarget*. 2017 Mar 28; 8(13): p. 21871–83.
28. Al-Abbasi DS, Al-Janabi AA, Al-Toriah KM, Jabor TA, Yasseen AA. Expression of VEGF in urinary bladder transitional cell carcinoma in an iraqi population subjected to depleted uranum. *Appl Immunohistochem Mol Morphol*. 2009;17(4):5.
29. Wong MCS, Fung FDH, Leung C, Cheung WWL, Goggins WB, Ng CF. The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection. *Sci Rep*. 2018 Dec; 8(1): p. 1129.
30. Marcos-Gragera R, Mallone S, Kiemeney LA, Vilardell L, Malats N, Allory Y, et al. Urinary tract cancer survival in Europe 1999–2007: Results of the population-based study EUROCARE-5. *European Journal of Cancer*. 2015 Oct; 51(15): p. 2217–30.

31. Biagioli MC, Fernandez DC, Spiess PE, Wilder RB. Primary bladder preservation treatment for urothelial bladder cancer. *Cancer Control.* 2013 Jul; 20(3): p. 188–99.
32. Miyazaki J, Nishiyama H. Epidemiology of urothelial carcinoma. *Int J Urol.* 2017 Oct; 24(10): p. 730–4.
- 33 . Tilborg, Annechiena Geertruida van. The Molecular pathogenesis of bladder cancer. Dit proefschrift werd bewerkt binnen de afdeling Pathologie van de Faculteit der Geneeskunde en Gezondheidswetenschappen, Erasmus Universiteit Rotterdam. 2001.
34. Umbas R, Hardjowijoto S, Mochtar CA, Safriadi F, Djatisoesanto W, Oka AAG, et al. Panduan penanganan kanker kandung kemih tipe urotelial. Ikatan Ahli Urologi Indonesia (IAUI). 2014 : p. 56.
35. Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. *Nat Rev Cancer.* 2015 Jan.
36. Theodorescu D. Molecular pathogenesis of urothelial bladder cancer. *Histology and Histopathology University of Virginia.* 2003: p.16.
37. Seth P L, Mark P S, Cora N S. Textbook of bladder cancer. USA: Taylor and Francis Group; 2006.
38. Bostwick DG, Cheng L, editors. Urologic surgical pathology. Third edition. Philadelphia, PA: Elsevier/Saunders; 2014. p. 966.
39. Magers MJ, Lopez-Beltran A, Montironi R, Williamson SR, Kaimakliotis HZ, Cheng L. Staging of bladder cancer. *Histopathology.* 2019 Jan;74(1): p. 112–34.
40. Goyal S, Singh UR, Sharma S, Kaur N. Correlation of mitotic indices, AgNor count, Ki-67 and Bcl-2 with grade and stage in papillary urothelial bladder cancer. *Urol J.* 2014 Mar 3;11(1): p. 1238–47.
41. Enache M, Simionescu C, Lasca LC. Ki67 and Bcl-2 immunoexpression in primitive urothelial bladder carcinoma. 2012;53(3): p. 521–5.
42. Anastasiadis A, de Reijke TM. Best practice in the treatment of nonmuscle invasive bladder cancer. *Therapeutic Advances in Urology.* 2012;20.

43. McDonald JR, Thompson GJ. Carcinoma of the urinary bladder: a pathologic study with special reference to invasiveness and vascular invasion. *J Urol.* 1948;60(3): p. 435–445.
44. Wu C, Sha N, Xie L, Chen T, Zhang Y, Xu H, et al. Impact of lymphovascular invasion on recurrence and progression rates in patients with pT1 urothelial carcinoma of bladder after transurethral resection. *OTT.* 2015 Nov ; p. 3401.
45. Mirza A, Choudhury A. Bladder preservation for muscle invasive bladder cancer. *BLC.* 2016 Apr 27; 2(2): p. 151–63.
46. Mathieu R, Lucca I, Rouprêt M, Brigandt A, Shariat SF. The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. *Nat Rev Urol.* 2016 Aug; 13(8): p. 471–9.
47. Streeper NM, Simons CM, Konety BR, Muirhead DM, Williams RD, O'Donnell MA, et al. The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer. *BJU International.* 2009 Feb;103(4): p. 475–9.
48. Kunju LP, You L, Zhang Y, Daignault S, Montie JE, Lee CT. Lymphovascular Invasion of Urothelial Cancer in Matched Transurethral Bladder Tumor Resection and Radical Cystectomy Specimens. *Journal of Urology.* 2008 Nov; 180(5): p. 1928–32.
49. Streeter EH, Harris AL. Angiogenesis in bladder cancer—prognostic marker and target for future therapy. *Surgical Oncology.* 2002; p.16.
50. Narayanan S, Srinivas S. Incorporating VEGF-targeted therapy in advanced urothelial cancer. *Ther Adv Med Oncol.* 2017 Jan; 9(1): p.33–45.
51. Oliver M, Waxman ES. The role of anti-angiogenic agents (VEGF). In: Davies M, Eaby-Sandy B, editors. *Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners.* Cham: Springer International Publishing; 2019. p. 85–104.
52. Dvorak AM, Senger DR, Galli SJ, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. *Science.* 1983;219: p. 983–5.

53. Ferrara N, Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. *Science*. 1989;246: p. 1306–9.
54. Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. *Current Opinion in Cell Biology*. 2009 Apr; 21(2): p. 154–65.
55. Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. *Cardiovascular Research*. 2005 Feb 15; 65(3): p. 550–63.
56. Dvorak HF. Vascular permeability factor/ vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. *J Clin Oncol*. 2002;20: p. 4368–80.
57. Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. *Am J Physiol Cell Physiol*. 2001;280: p. C1375–86.
58. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. *Nat Med*. 2003;9: p. 669–76.
59. Benjamin LE, Golijanin D, Itin A, et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. *Clin Invest*. 1999;103: p. 159–65.
60. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. *Cardiovasc Res*. 2001;49: p. 568–81.
61. Choong PF, Nadesapillai AP. Urokinase plasminogen activator system: A multifunctional role in tumor progression and metastasis. *Clin Orthop*. 2003; p. S46-58.
62. Maynard MA, Ohh M. The role of hypoxia-inducible factors in cancer. *Cell Mol Life Sci*. 2007 Aug; 64(16): p. 2170–80.
63. Lv X, Li J, Zhang C, Hu T, Li S, He S, et al. The role of hypoxia-inducible factors in tumor angiogenesis and cell metabolism. *Genes & Diseases*. 2017 Mar; 4(1): p. 19–24.

64. Ferrara N, Dong J, Grunstein J, Tajada M, et al. VEGF-null cells require PDGFR signalingmediated stromal fibroblast recruitment for tumorigenesis. *EMBO J.* 2004;23: p. 2800–10.
65. Sherbet GV. Vascular endothelial growth factor. In: growth factors and their receptors in cell differentiation, cancer and cancer therapy. Elsevier; 2011. p. 55–64.
66. Adelmann T, Ioiart I, Ceausu R, Sarb S, Suciu C. Immunohistochemical expression of vascular endothelial growth factor does not correlate with microvessel density in invasive bladder carcinoma. *Research and Clinical Medicine.* 2018;II: p. 6.
67. Yang H, Wang Z, Guo Y, Wang Z. Correlation and significance of urinary soluble fas and vascular endothelial growth factor in bladder urothelial cancer. *Disease Markers.* 2015; p. 6.
68. Guntarno NC, Rahaju AS, Kurniasari N. The role of MMP-9 and VEGF in the invasion state of bladder urothelial carcinoma. *Indones Biomed J.* 2021 Mar 1 ; 13(1): p. 61–7.
69. El-Chennawi FA, Auf FA, Metwally SS, Mosaad YM, Shaaban AA, El-Baz MA, et al. Vascular endothelial growth factor, p53, and the H-ras oncogene in egyptian patients with bladder cancer. *World Journal of Gastrointestinal Oncology.* 2009 Oct 15; 1(1): p. 62–8.
70. Deniz H, Karakök M, Yagci F, Güldür ME. Evaluation of relationship between HIF-1 α immunoreactivity and stage, grade, angiogenic profile and proliferative index in bladder urothelial carcinomas. *Int Urol Nephrol.* 2010 Mar; 42(1): p. 103–7.
71. Ghafouri S, Burkenroad A, Pantuck M, Almomani B, Stefanoudakis D, Shen J, et al. VEGF inhibition in urothelial cancer: the past, present and future. *World J Urol.* 2020 May 2.
72. Sastroasmoro, Ismail. Dasar-dasar metodologi penelitian klinis. Jakarta: Sagung Seto; 2014.
73. Syafa'ah AN, Maulani H, Suciati T. Angka kejadian karsinoma urothelial di bagian patologi anatomi RSUP dr. mohammad hoesin palembang periode tahun 2009-2013. 2015;(1): p.7.

74. Pandu PA, Pandu IN, Marie YA. Insidensi Penyakit Kanker Buli-buli di RSUD Provinsi Nusa Tenggara Barat periode 2017-2018. JKU. 2019 Jun 28;8(2): p.1.
75. Lejbkowicz F, Goldberg-Cohen I, Levy AP. New horizons for VEGF. Is there a role for nuclear localization? *Acta Histochemica*. 2005 Feb; 106(6): p.405–11.
76. Rosenbaum-Dekel Y, Fuchs A, Yakirevich E, Azriel A, Mazareb S, Resnick MB, et al. Nuclear localization of long-VEGF is associated with hypoxia and tumor angiogenesis. *Biochemical and Biophysical Research Communications*. 2005 Jun; 332(1): p.271–8.
77. Morfoisse F, Renaud E, Hantelys F, Prats A-C, Garmy-Susini B. Role of hypoxia and vascular endothelial growth factors in lymphangiogenesis. *Molecular & Cellular Oncology*. 2015 Oct 2; 2(4):e1024821.
78. Siregar GP. Vascular Endothelial Growth Factor Polymorphism in Bladder Cancer: A Review. *Open Access Maced J Med Sci*. 2020 Mar 5 ;8(F): p.31–6.
79. Yang C-C, Chu K-C, Yeh W-M. The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. *Urologic Oncology*. 2004; p.6.